Caribou Biosciences Inc. to Showcase at BofA Securities 2025 Health Care Conference

In a significant move for the biopharmaceutical sector, Caribou Biosciences Inc., a clinical-stage CRISPR genome-editing company, is set to make its mark at the BofA Securities 2025 Health Care Conference. The company, known for its innovative approach to developing transformative therapies, will have its President and CEO, Rachel Haurwitz, PhD, participate in a fireside chat on May 13th at 2:35 PM PDT.

Caribou Biosciences, headquartered in Berkeley, California, specializes in therapeutic bioproduction, microbial strains, and agricultural biotechnology products. The company’s cutting-edge Cas12a chRDNA technology is at the forefront of its genome-editing platform, enabling the development of cell therapies with enhanced precision. These therapies are designed to combat devastating diseases, particularly hematologic malignancies, through off-the-shelf CAR-T cell therapies such as CB-010 and CB-011.

Despite facing a challenging financial landscape, with a close price of $0.76 as of May 6, 2025, and a market capitalization of $74.57 million, Caribou Biosciences remains focused on its mission to provide broad access and rapid treatment for patients. The company’s participation in the BofA Securities conference underscores its commitment to advancing its pipeline and engaging with investors and industry stakeholders.

The fireside chat, led by Dr. Haurwitz, will provide insights into Caribou’s strategic direction and the potential impact of its technologies. The webcast will be accessible on Caribou’s website for at least 30 days following the event, offering a valuable opportunity for investors and industry observers to gain a deeper understanding of the company’s initiatives.

As Caribou Biosciences continues to navigate the complexities of the health care sector, its presence at the BofA Securities conference highlights its dedication to innovation and patient care. With a focus on transformative therapies, the company is poised to make significant strides in the biopharmaceutical landscape.

For more information about Caribou Biosciences and its offerings, visit their website at www.cariboubio.com . Stay connected with the company’s latest developments by following them on social media and visiting their investor relations page.